Öz

 

Objective: Hepatomegaly and/or splenomegaly (HSM) are common clinical findings with a broad differential diagnosis, including infectious, hematologic, malignant, and inherited metabolic diseases. Although inborn errors of metabolism (IEM) are rare, they constitute critical and often treatable causes of HSM. This study aimed to evaluate pediatric patients presenting with hepatomegaly and/or splenomegaly for underlying metabolic disorders and to identify diagnostic indicators that may facilitate early recognition and appropriate management of IEM.

Materials and Methods: This retrospective study evaluated 223 children presenting with hepatomegaly, splenomegaly, or hepatosplenomegaly between June 2023 and October 2025 at a pediatric metabolic clinic. Only those with genetically confirmed diagnoses of IEM were included in the final cohort. Clinical features and laboratory findings were evaluated.

Results: Twenty-seven patients (15.4%) received a confirmed IEM diagnosis. The most frequent disorders were glycogen storage diseases (n=13, 7.4%), followed by Gaucher disease (n=6, 3.4%), acid sphingomyelinase deficiency (n=3, 1.7%), and single cases of Niemann-Pick type C, Mucopolysaccharidosis type II, GM1 gangliosidosis, hereditary fructose intolerance, and galactosemia. Consanguinity was present in 84.6%, and characteristic systemic findings such as hypoglycemia, hyperlipidemia, cytopenias, cholestasis, neurological involvement, or coarse facies served as critical diagnostic clues.

Conclusion: Inborn errors of metabolism should be considered in children presenting with hepatomegaly and/or splenomegaly, particularly in the presence of accompanying systemic findings, especially in regions with high consanguinity rates. Recognition of diagnostic clues may facilitate earlier referral, reduce diagnostic delays, and enable timely initiation of disease specific treatments, including enzyme replacement therapy or dietary modification.

Anahtar Kelimeler: Hepatomegaly, inborn errors of metabolism , splenomegaly

Kaynakça

  1. Jerves Serrano T, Gold J, Cooper JA et al. Hepatomegaly and Splenomegaly: An Approach to the Diagnosis of Lysosomal Storage Diseases. J Clin Med. 2024;13(5):1465. https://doi.org/10.3390/jcm13051465
  2. Özdikici M. The relationship between splenic length in healthy children from the Eastern Anatolia region and sex, age, body height and weight. J Ultrason 2018; 18:5-8. https://doi.org/10.15557/JoU.2018.0001
  3. Konus¸ OL, Ozdemir A, Akkaya A, Erbas¸ G, Celik H, Isık S. Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography. AJR Am J Roentgenol 1998; 171:1693-8. https://doi.org/10.2214/ajr.171.6.9843315
  4. Curovic Rotbain E, Lund Hansen D, Schaffalitzky de Muckadell O, Wibrand F, Meldgaard Lund A, Frederiksen H. Splenomegaly - Diagnostic validity, work-up, and underlying causes. PLoS One. 2017;12:e0186674. https://doi.org/10.1371/journal.pone.0186674
  5. Benzamin M, Sayeed M, Islam MS, Alam R, Rukunuzzaman M, Mazumder MW, Karim ASB. Study of etiological profile of children presented with hepatomegaly and/or splenomegaly: an experience from Pediatric Gastroenterology Department, Bangabandhu Sheikh Mujib Medical University. Paed Neph J Bang. 2018;3:9-17.
  6. Bulut FD, Bilginer Gürbüz B. Etiological Evaluation of Patients with Hepatomegaly, Splenomegaly and Hepatosplenomegaly Referred to a Pediatric Metabolism Unit. Acibadem Univ Saglik Bilim Derg. 2022;13:369-73. https://doi.org/10.31067/acusaglik.987546
  7. Stone WL, John TA, Anastasopoulou C, et al. Glycogen storage disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459277/
  8. Paschall A, Khan AA, Enam SF, et al. Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: A clinical study and review of the literature. Mol Genet Metab. 2021;134:223-34. https://doi.org/10.1016/j.ymgme.2021.10.002
  9. Massese M, Tagliaferri F, Dionisi-Vici C, Maiorana A. Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI. Orphanet J Rare Dis. 2022;17:241. https://doi.org/10.1186/s13023-022-02387-6
  10. Rossiaud L, Fragner P, Barbon E, Gardin A, Benabides M, Pellier E, Cosette J, El Kassar L, Giraud-Triboult K, Nissan X, Ronzitti G, Hoch L. Pathological modeling of glycogen storage disease type III with CRISPR/Cas9 edited human pluripotent stem cells. Front Cell Dev Biol. 2023;11:1163427. https://doi.org/10.3389/fcell.2023.1163427
  11. Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27. https://doi.org/10.1038/s41572-018-0025-4
  12. McGovern MM, Wasserstein MP, Bembi B, Giugliani R, Mengel KE, Vanier MT, Zhang Q, Peterschmitt MJ. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis. 2021;16:212. https://doi.org/10.1186/s13023-021-01842-0
  13. Cappellini MD, Motta I, Barbato A, Giuffrida G, Manna R, Carubbi F, Giona F. Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis. Eur J Intern Med. 2023;108:81-4. https://doi.org/10.1016/j.ejim.2022.11.028
  14. Mistry PK, Cassiman D, Jones SA, Lachmann R, Lukina E, Prada CE, Wasserstein MP, Thurberg BL, Foster MC, Patel RM, Underhill LH, Peterschmitt MJ. Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals. Hepatol Commun. 2025;9(1):e0621. https://doi.org/10.1097/HC9.0000000000000621
  15. Diaz GA, Jones SA, Scarpa M et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med. 2022;24:2209. https://doi.org/10.1016/j.gim.2022.08.011
  16. Thurberg BL, Diaz GA, Lachmann RH et al. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment. Mol Genet Metab. 2020;131:245-52. https://doi.org/10.1016/j.ymgme.2020.06.010
  17. Wasserstein M, Lachmann R, Hollak C et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. Genet Med. 2022l;24:1425-36. https://doi.org/10.1016/j.gim.2022.03.021
  18. Antonello BB, Giovacchini G, Albuquerque ALB et al. Efficacy and Safety of Olipudase Alfa for the Treatment of Acid Sphingomyelinase Deficiency (ASMD): A Systematic Review and Meta-Analysis. Am J Med Genet A. 2025; e64258. https://doi.org/10.1002/ajmg.a.64258
  19. Lachmann RH, Diaz GA, Wasserstein MP, Armstrong NM, Yarramaneni A, Kim Y, Kumar M. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults. Orphanet J Rare Dis. 2023;18:94. https://doi.org/10.1186/s13023-023-02700-x
  20. Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007;30(5):631-41. https://doi.org/10.1007/s10545-007-0661-4
  21. Salsano E, Umeh C, Rufa A, Pareyson D, Zee DS. Vertical supranuclear gaze palsy in Niemann-Pick type C disease. Neurol Sci. 2012;33:1225-32. https://doi.org/10.1007/s10072-012-1155-1
  22. Köylü- Kireker O, Kasapkara ÇS. Ophthalmological findings in metabolic diseases. Turk J Pediatr Dis 2023;17:256-66 https://doi.org/10.12956/tchd.1271228
  23. Kılıç M, Kasapkara ÇS, Kılavuz S, Mungan NÖ, Biberoğlu G. A possible biomarker of neurocytolysis in infantile gangliosidoses: aspartate transaminase. Metab Brain Dis. 2019;34(2):495-503. dhttps://doi.org/10.1007/s11011-019-0391-y
  24. Kern J, Böhringer J, Timmann D, Trollmann R, Stendel C, Kamm C, et al. Clinical, imaging, genetic, and disease course characteristics in patients with GM2 gangliosidosis: beyond age of onset. Neurology. 2024;102(1):e207898 https://doi.org/10.1212/WNL.0000000000207898
  25. Garbowski L, Walasek M, Firszt R, Chilińska-Kopko E, Błażejewska-Gała P, Popielnicki D, Dzięcioł-Anikiej Z. A Case Study of a Rare Disease (Fructosemia) Diagnosed in a Patient with Abdominal Pain. J Clin Med. 2024;13:3394. https://doi.org/10.3390/jcm13123394
  26. Gunduz M, Ünal-Uzun Ö, Koç N, Ceylaner S, Özaydın E, Kasapkara ÇS. Molecular and clinical findings of Turkish patients with hereditary fructose intolerance. J Pediatr Endocrinol Metab. 2021;34:1017-22. https://doi.org/10.1515/jpem-2021-0303
  27. Schweitzer-Krantz S. Early diagnosis of inherited metabolic disorders towards improving outcome: the controversial issue of galactosaemia. Eur J Pediatr. 2003;162:S50-3. https://doi.org/10.1007/s00431-003-1352-2

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Atıf Lisansı (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır

1.
Burgaç E, Yoldaş Çelik M, Köşeci B. Hepatosplenomegaly in children: A gateway to inherited metabolic disorders. Turk J Pediatr Dis. 2026;Early View:1-5. https://doi.org/10.12956/TJPD.2025.1276